Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push

• 3 Lesser-Known Healthcare Names With Major Upside successful Store

Amneal Pharmaceuticals (NASDAQ:AMRX) outlined plans to get Kashiv BioSciences and reported preliminary first-quarter results during an capitalist call, with executives describing the woody arsenic a strategical determination to physique a vertically integrated biosimilars level and widen the company’s maturation illustration into the adjacent decade.

President and Co-CEO Chirag Patel said the Kashiv acquisition represents “a defining infinitesimal for Amneal,” and is intended to make “a afloat integrated planetary biosimilars leader.” Patel said the operation is designed to supply nonstop entree to what absorption characterized arsenic much than $300 cardinal of worldwide biologic nonaccomplishment of exclusivity implicit the adjacent decade, pairing Kashiv’s R&D and manufacturing capabilities with Amneal’s commercialized scale.

→ Amazon Stock Up 30%: Is AMZN Still a Buy Before Earnings?

• 6 reasons to bargain Teva Pharmaceuticals banal sooner than later

According to Patel, the transaction builds connected a concern betwixt the companies that has lasted much than a decade, which helium said reduces execution risk. He besides said the woody adds biosimilars arsenic a cardinal maturation pillar for Amneal’s “affordable medicines” strategy and diversifies the concern with a presumption toward extending maturation “well into 2030s.”

Co-CEO Chintu Patel said Kashiv is simply a biologics level built implicit 12 years with “more than $900 cardinal invested,” much than 600 employees, and 4 R&D and manufacturing sites spanning the U.S. and India. He said the level supports parallel improvement crossed modalities including monoclonal antibodies, fusion proteins, bispecifics, and cytokines.